|
Global X Marijuana Life Sciences Index ETF (HMMJ)
|
As of June 30, 2025
|
|
(Sector Equity)
|
|
Underlying Index
|
North American Medical Marijuana Index
|
Inception Return
(4/4/2017)
|
-16.12 %
|
|
Day High/Low
|
$7.22 / $7.07
|
|
YTD Return
|
-26.00 %
|
|
52Week High/Low
|
$11.40 / $5.77
|
|
|
|
|
|
NAVPS
(7/18/2025)
|
$7.11
|
|
Change
|
$-0.05 / -0.72 %
|
Open / Close
(7/18/2025)
|
$7.14
/
$7.08
|
|
|
|
Management Fee
|
0.75 %
|
|
Traded Volume
|
9,743
|
|
Assets ($mil)
|
-
|
|
Rank (1Yr)
|
-
|
|
Std Dev (3Yr)
|
50.70 %
|
|
Beta (3Yr)
|
1.46
|
|
Volatility Ranking (3Yr)
|
10/10
|
|
RRSP Eligibility
|
Yes
|
|
Open to Invest
|
Open
|
|
Annual Dividend
|
$0.33
|
|
Annual Yield
|
4.64 %
|
|
|
Objective
The investment objective of the ETF is to seek to replicate, to the extent possible, the performance of the North American Marijuana Index, net of expenses. The North American Marijuana Index is designed to provide exposure to the performance of a basket of North American publicly listed companies with significant business activities in the marijuana industry.
|
Fund Manager
Global X Investments Canada Inc.
Portfolio Manager
Global X Investments Canada Inc.
Sub-Advisor
-
|
|
Asset Allocation
(As of June 30, 2025)
|
Sector Allocation
(As of June 30, 2025)
|
Geographic Allocation
(As of June 30, 2025)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Jazz Pharmaceuticals PLC | International Equity | Healthcare | European Union | 16.94% |
| Cronos Group Inc | Canadian Equity | Healthcare | Canada | 12.83% |
| Innovative Industrial Properties Inc | US Equity | Real Estate | United States | 12.21% |
| Scotts Miracle-Gro Co | US Equity | Basic Materials | United States | 10.92% |
| SNDL Inc | Canadian Equity | Consumer Goods | Canada | 7.26% |
| Tilray Brands Inc | US Equity | Healthcare | United States | 5.51% |
| Aurora Cannabis Inc | Canadian Equity | Healthcare | Canada | 4.45% |
| Canopy Growth Corp | Canadian Equity | Healthcare | Canada | 4.40% |
| Cash and Cash Equivalents | Cash and Equivalents | Cash and Cash Equivalent | Canada | 4.21% |
| Skye Bioscience Inc | US Equity | Healthcare | United States | 3.78% |
Performance Data
(As of June 30, 2025)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
-1.25
|
-4.85
|
-26.00
|
-26.00
|
-31.82
|
-19.84
|
-22.78
|
-
|
|
Benchmark
|
2.91
|
8.53
|
10.17
|
10.17
|
26.37
|
16.09
|
15.02
|
9.61
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Calendar Return (%)
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
Fund
|
-0.29
|
-18.82
|
-52.54
|
-18.99
|
-1.28
|
-33.82
|
-19.82
|
-
|
-
|
-
|
|
Benchmark
|
21.65
|
11.75
|
-5.84
|
25.09
|
5.60
|
22.88
|
-8.89
|
9.10
|
21.08
|
-8.32
|
|
Quartile Ranking
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|